Immunome Inc. 8-K

What Happened

• Immunome, Inc. announced its financial results for the quarter ended March 31, 2026 and provided a business update in a press release dated May 12, 2026. The company filed an 8-K (Item 2.02) on May 12, 2026 to report these quarterly results and to incorporate the press release by reference.

Key Details

• Filing date: May 12, 2026.
• Period reported: quarter ended March 31, 2026.
• Press release attached as Exhibit 99.1 and incorporated by reference in the 8-K.
• Report signed on behalf of the company by Max Rosett, Chief Financial Officer.

Why It Matters

• Quarterly results and the accompanying business update are material information for investors seeking current data on Immunome’s financial performance, operations, and progress. Investors should review the May 12, 2026 press release (Exhibit 99.1) and any related filings for the detailed revenue, expenses, cash position, and program updates referenced in the 8-K.